Premium
Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials
Author(s) -
Morabito Fortunato,
Tripepi Giovanni,
Del Poeta Giovanni,
Mauro Francesca Romana,
Reda Gianluigi,
Sportoletti Paolo,
Laurenti Luca,
Coscia Marta,
Herishanu Yair,
Bossio Sabrina,
Varettoni Marzia,
Murru Roberta,
Chiarenza Annalisa,
Visentin Andrea,
Condoluci Adalgisa,
Moia Riccardo,
Pietrasanta Daniela,
Loseto Giacomo,
Consoli Ugo,
Scortechini Ilaria,
Rossi Francesca Maria,
Zucchetto Antonella,
AlJanazreh Hamdi,
Vigna Ernesto,
Martino Enrica Antonia,
Cassin Ramona,
D′Arrigo Graziella,
Galimberti Sara,
Rago Angela,
Angeletti Ilaria,
Biagi Annalisa,
Del Giudice Ilaria,
Bomben Riccardo,
Neri Antonino,
Fronza Gilberto,
Monti Paola,
Menichini Paola,
Olivieri Jacopo,
Cutrona Giovanna,
Rossi Davide,
Cuneo Antonio,
Di Raimondo Francesco,
Gaidano Gianluca,
Polliack Aaron,
Trentin Livio,
Foà Robin,
Ferrarini Manlio,
Gattei Valter,
Gentile Massimo
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26201
Subject(s) - bendamustine , ibrutinib , rituximab , medicine , chronic lymphocytic leukemia , oncology , second line therapy , clinical trial , venetoclax , leukemia , lymphoma , chemotherapy